Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CBD for LGS: Fewer seizures, but thrombocytopenia risk

Key clinical point: Cannabidiol reduces seizures but may cause thrombocytopenia in some patients.

Major finding: Average seizure reduction was greater than 60%, but one-third on valproic acid had thrombocytopenia.

Study details: Open-label extension trial of 366 patients and single-center retrospective study of 83 patients on CBD therapy for Lennox Gastaut syndrome.

Disclosures: Anup D. Patel, MD, disclosed financial relationships with GW Research and Greenwich Biosciences. Nancy A. McNamara, MD, has no relevant disclosures.


Patel AD et al. CNS-ICNA 2020, Presentation PL12; McNamara NA et al. CNS-ICNA 2020, Presentation PL29.